Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > l love reading these highlighted words !
View:
Post by Oden6570 on Oct 02, 2022 9:54am

l love reading these highlighted words !

The serendipitous discovery of cisplatin opened the door to platinum-based cancer therapy. Even in the era of immunotherapy and precision medicine, platinum compounds are still the mainstay of chemotherapy regimens for various cancers. However, platinum compounds suffer from drug resistance, off-target problems, and various side effects including nephrotoxicity, myelosuppression, ototoxicity, pulmonary toxicity, and neurotoxicity. The emergence of luminescent metal complexes offers tremendous opportunities to address the issues of platinum-based cancer therapy. Luminescent metal complexes, especially noble metal complexes (iridium, ruthenium, gold, osmium, etc.) and lanthanide complexes (europium, neodymium, ytterbium, etc) have the advantage of desirable optical properties and tunable therapeutic effects. These complexes have been developed for targeted cancer therapy, photodynamic therapy, combination cancer therapy with other immunotherapy or targeted therapy, targeted delivery, and theranostics. Considerable efforts in this area have resulted in the development of clinical candidates for cancer diagnosis and therapy such as TLD1433, representing the next generation of metallodrugs.

Advances in Cancer Imaging and Therapy Based on Luminescent Metal Complexes | Frontiers Research Topic (frontiersin.org)
Comment by Oilminerdeluxe on Oct 02, 2022 11:43am
Since it is a boring Sunday, when might another trial start, realistically? Would not mind having two  cancer trials running at the same time. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250